As we all look forward to another prostate cancer awareness month, I find myself reeling with the advances the field has seen in the past year, particularly in the area of hormone sensitive metastatic prostate cancer. We learned that men may live longer if we can radiate the primary tumor if they have low volume metastatic disease. We also learned that enzalutamide and
The approach to the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has undergone a dramatic transformation over the last few years.  This is probably most surprising because of the lack of therapeutic developments for those patients for several decades prior.